Position in CRVS
as of Jun 30, 2026
· filed Aug 12, 2026
Position Value
$152,313
+$2,254 QoQ
Shares Held
10,195
-0.6% QoQ
Ownership
0.012%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#133
of 172 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in CRVS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Truvestments Capital LLC holds $2,122,733 across 78 Biotechnology names. CRVS ranks #2 (7.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | EXEL |
Exelixis, Inc.
|
7,833 | $426,193 | |
| 2 | CRVS |
Corvus Pharmaceuticals, Inc.
This page
|
10,195 | $152,313 | |
| 3 | PTGX |
Protagonist Therapeutics, Inc
|
1,156 | $141,702 | |
| 4 | ROIV |
Roivant Sciences Ltd.
|
3,788 | $134,057 | |
| 5 | CTMX |
CytomX Therapeutics, Inc.
|
27,988 | $104,955 | |
| 6 | TGTX |
Tg Therapeutics, Inc.
|
1,764 | $96,914 | |
| 7 | RIGL |
Rigel Pharmaceuticals Inc
|
2,387 | $93,379 | |
| 8 | BBIO |
BridgeBio Pharma, Inc.
|
1,229 | $91,535 |
All Filings in CRVS
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $152,313 | 10,195 | Shares | Sole | 2026-08-12 | |
| 2026-03-31 | $150,059 | 10,257 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $78,978 | 10,257 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $40,630 | 5,513 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $19,100 | 4,775 | Shares | Sole | 2025-08-13 | |
| No filing history on record for this holder in this stock. | ||||||